Neurocrine Biosciences (STU:NB3) Tariff Resilience Score: 7/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NB3 Neurocrine Biosciences Inc STU:NB3
93 GF Score
Price €153.15
GF Value €166.59
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Tariff Resilience Score?

Neurocrine Biosciences STU:NB3 -1.23% 93 Tariff Resilience Score is 7 as of Jul. 14, 2026. GuruFocus rates STU:NB3 with a GF Score™ of 93/100 and a GF Value™ of €166.59 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 97.08% on this metric.

Neurocrine Biosciences has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Neurocrine Biosciences has Pharmaceutical company with some international supply chain exposure. Moderate resilience due to strong pricing power and potential for industry-specific exemptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Neurocrine Biosciences might have Highly Resilient.

Neurocrine Biosciences  (STU:NB3) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Neurocrine Biosciences Tariff Resilience Score Related Terms

STU:NB3 vs VTRS, ELAN, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurocrine Biosciences Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Tariff Resilience Score falls into.


STU:NB3
93GF Score
Neurocrine Biosciences Inc STU:NB3
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Neurocrine Biosciences (STU:NB3) has a Tariff Resilience Score of 7 as of Jul. 14, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Neurocrine Biosciences ranks #30 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Neurocrine Biosciences' Tariff Resilience Score too high?
Neurocrine Biosciences' current Tariff Resilience Score is 7. Based on the distribution chart, Neurocrine Biosciences ranks #30 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Tariff Resilience Score compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #30 out of 1029 companies for Tariff Resilience Score. This places Neurocrine Biosciences in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Neurocrine Biosciences's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (STU:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €166.59, compared to a current price of €153.15 — trading 8.1% below its estimated fair value. The current Tariff Resilience Score is 7. Neurocrine Biosciences' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Neurocrine Biosciences (STU:NB3), the current Tariff Resilience Score is 7 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (STU:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €153.15 is trading 8.1% below its estimated GF Value™ of €166.59. GuruFocus considers Neurocrine Biosciences to be Fairly Valued.

Key valuation signals for STU:NB3:

  • Tariff Resilience Score: 7
  • GF Value™: €166.59 vs. price of €153.15 (8.1% below fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the STU:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
93GF Score

Get the complete analysis for STU:NB3

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€153.15
Price
€166.59
GF Value